


This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1. (previously presented) A compound of formula (I):



wherein

P^1 and P^2 independently represent the residue of a polyethylene glycol (PEG) molecule;

Z^1 , Z^2 and Z^3 independently represent the residue of a polyclonal, monoclonal, multi-valent, multi-specific, humanized or chimeric antibody, a single chain antibody, a Fab fragment, a Fab' or $F(ab')_2$ fragment, or an epitope-binding fragment thereof;

X^1 , X^2 and X^3 independently represent CR^1 or N;

A^1 and A^2 independently represent -CONH-, -NHCO-, -OC(O)N(R^2)-, -N(R^2)C(O)O- or -NHCONH-;

B^1 , B^2 and B^3 independently represent -CONH- or -CO-;

V^1 , V^2 and V^3 independently represent a covalent bond or -(CH_2) v -;

W^1 and W^2 independently represent a covalent bond or -(CH_2) w -;

Y^1 , Y^2 and Y^3 independently represent -(CH_2) y -;

L^1 , L^2 and L^3 independently represent a maleimide residue;

M^1 and M^2 independently represent a covalent bond or -(CH_2) m -;

R^1 represents hydrogen or C_{1-4} alkyl;

R^2 represents hydrogen or C_{1-4} alkyl;

n is zero, 1 or 2;

v is 1, 2, 3 or 4;


w is 1, 2, 3 or 4;

y is 1, 2, 3, 4, 5 or 6; and

m is 1, 2 or 3.

2. (previously presented) A compound as claimed in claim 1 wherein Z¹, Z² and Z³ independently represent the residue of a whole antibody or the residue of a functionally active antibody fragment or derivative.

3. (withdrawn) A compound of formula (II):



(II)

wherein

L¹¹, L¹² and L¹³ represent groups that attach residues Z¹, Z² and Z³, respectively, or that are converted into groups that attach residues Z¹, Z² and Z³, respectively;

Z¹, Z² and Z³ independently represent the residue of a biologically active moiety;

P¹ and P² independently represent a polymer residue;

X¹, X² and X³ independently represent CR¹ or N;

A¹ and A² independently represent -CONH-, -NHCO-, -OC(O)N(R²)-, -N(R²)C(O)O- or -NHCONH-;

B¹, B² and B³ independently represent -CONH- or -CO-;

V¹, V² and V³ independently represent a covalent bond or -(CH₂)_v-;

W¹ and W² independently represent a covalent bond or -(CH₂)_w-;

Y¹, Y² and Y³ independently represent -(CH₂)_y-;

M¹ and M² independently represent a covalent bond or -(CH₂)_m-;

R¹ represents hydrogen or C₁₋₄ alkyl;

R² represents hydrogen or C₁₋₄ alkyl;

n is zero, 1 or 2;


v is 1, 2, 3 or 4;

w is 1, 2, 3 or 4;

y is 1, 2, 3, 4, 5 or 6; and

m is 1, 2 or 3.

4. (withdrawn) A compound as claimed in claim 3 represented by formula (III):



(III)

5. (cancelled)

6. (withdrawn) A compound as claimed in claim 1 wherein R¹ is hydrogen.

7. (previously presented) A compound as claimed in claim 1 wherein n is zero.

8. (previously presented) A compound as claimed in claim 1 that is
DiFab'-conjugated N,N'-bis-[4-maleimidylbutyl]-2,3-bis-(3-(methoxy-polyethoxy)-propionylamino)-succinamide;
DiFab'-conjugated 3-maleimidyl-N-(2-{[3-maleimidyl-propionyl]-[(2-(methoxy-polyethoxy)-ethylcarbamoyl)-methyl]-amino}-ethyl)-N-[(2-(methoxy-polyethoxy)-ethylcarbamoyl)-methyl]-propionamide; or

DiFab'-conjugated 3-maleimidyl-N-(2-{[3-(maleimidyl)-propionyl]-[2-(2-(methoxy-polyethoxy)-ethylcarbamoyl)-ethyl]-amino}-ethyl)-N-[2-(2-(methoxy-polyethoxy)-ethylcarbamoyl)-ethyl]-propionamide.

9. (withdrawn) A compound as claimed in claim 4 that is
N,N'-Bis-[4-maleimidylbutyl]-2,3-bis-(3-(methoxy-polyethoxy)-propionylamino)-succinamide;
3-Maleimidyl-N-(2-{[3-maleimidyl-propionyl]-[(2-(methoxy-polyethoxy)-ethylcarbamoyl)-methyl]-amino}-ethyl)-N-[(2-(methoxy-polyethoxy)-ethylcarbamoyl)-methyl]-propionamide; or
3-Maleimidyl-N-(2-{[3-(maleimidyl)-propionyl]-[2-(2-(methoxy-polyethoxy)-ethylcarbamoyl)-ethyl]-amino}-ethyl)-N-[2-(2-(methoxy-polyethoxy)-ethylcarbamoyl)-ethyl]-propionamide.

10. (previously presented) A pharmaceutical composition comprising a compound as claimed in claim 1 in association with one or more pharmaceutically acceptable carriers, excipients or diluents.